Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$7.09 ▼ -0.04
(-0.56%)
MKT CAP: $320.2M • VOL: 625.5K
52W L $3 52W H $10
ROARABLE / RQD
E • 26/100
PIOTROSKI
3 / 9
AGEN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $114.2M | $103.5M | $156.3M |
| YoY Revenue Growth % | +10.4% | -33.8% | — |
| Gross Profit | $113.2M | $103.0M | — |
| Gross Margin % | 98.0% | 98.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$20.2M | -$120.5M | -$159.5M |
| Operating Margin % | -17.7% | -80.0% | -80.0% |
| Net Income (GAAP) | -$3.1M | -$232.3M | -$257.4M |
| EBITDA (Normalized) | -$20.2M | -$120.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$77.2M | -$158.3M | -$224.2M |
| Capital Expenditures (CapEx) | $6.0K | $576.0K | — |
| Free Cash Flow (FCF) | -$77.2M | -$158.9M | -$224.2M |
| FCF Margin % | -67.6% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.0M | $40.4M | — |
| Total Debt (Short + Long Term) | $0 | $30.5M | — |
| Total Stockholders' Equity | -$271.1M | -$326.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AGEN.